Results
tumor, benign bone disease
TUMOR, LIVER METASTASES, DISEASE, CASTRATION-RESISTANT PROSTATE CANCER, -20
Thirty-nine patients were recruited between July 2015 and June 2017. Three patients were excluded from analysis: 1 for detection of liver metastases on baseline imaging, 1 for prior docetaxel for castration-resistant prostate cancer, and 1 who did not tolerate magnetic resonance imaging (MRI) (REASURE CONSORT diagram.Demographics and tumor characteristicsArab. ALP = alkaline phosphatase; IQR = interquartile range; PSA = prostate-specific antigen.Balancing factors for randomization.Extent of disease 0 = normal (abnormal because of benign bone disease); extent of disease 1 = fewer than 6 metastatic sites; extent of disease 2 = 6-20 metastatic sites; extent of disease 3 = more than 20 lesions but not a superscan; extent of disease 4 = superscan, defined as diffuse, intense, skeletal uptake of the tracer, with no kidney or background activity.